Search Videos and More
Document
Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Our Breast Oncology Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) plus pertuzumab, nearly doubled progression-free survival compared to the currently accepted standard treatment with taxane chemotherapy plus trastuzumab and pertuzumab (THP) for first-line therapy of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
News
Dana-Farber Research News 06.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 through May 15.
News
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
News
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the current standard treatment.
News
EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk
Dana-Farber Cancer Institute investigators launch a first-of-its-kind study to use a novel blood test to identify people who have never used tobacco but are at a high risk of lung cancer and offer them complimentary lung cancer screening.
News
New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor
A groundbreaking study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children.
Course
CME: Early Detection and Interception of Cancer
Through this course we will provide a comprehensive review of current cancer screening guidelines, provide guidance regarding high-risk populations and their management, educate regarding emerging technologies for early cancer detection, and provide referral pathways for complex patients.
News
Dana-Farber Research News 05.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 through April 30.
News
Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival
Dana-Farber researchers have discovered ancient bacterial defenses and anti-defenses that may persist in some form in humans today and could provide insights into new approaches to cancer research and treatment.
News
New Insights into Immunotherapy Targets for Pancreatic Cancer
Cancer research often focuses on gene mutations in the parts of the human genome that produce cellular machinery called proteins. But the rest of the genome — sometimes called the “dark genome” — can also play a role.